NASH Data, ASCO abstracts released, and M&A Activity. Read below for a look at major news from biopharma companies..
🧬 Verastem Oncology
Announced updated data from Part A of the ongoing registration-directed RAMP 201 trial evaluating avutometinib mono & combo w/ defactinib in patients with recurrent low-grade serous ovarian cancer. Combo tx resulted in an objective response rate (ORR) of 45% (13/29) and tumor shrinkage in 86% (25/29) of evaluable patients.
🧬 Hepion Pharmaceuticals
Announced positive topline results from their recently completed Phase 2 ALTITUDE-NASH clinical trial. ALTITUDE-NASH met its primary endpoint by demonstrating improved physiologic liver function. Company noted this "enhances and de-risks future studies, including potential Phase 3 trials".
🧬 AVROBIO
Announced an agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5 million in cash.
🧬 Elevation Oncology
Will be presenting a poster at American Society of Clinical Oncology (ASCO) from their ongoing Phase 1 dose escalation and dose expansion study evaluating SYSA1801 in patients with Claudin 18.2-positive advanced solid tumors being conducted in China. They remain on track to initiate a Phase 1 clinical trial in the U.S. evaluating EO-3021 in the second half of 2023.
🧬 Apexigen
Announced a definitive agreement by which Pyxis Oncology will acquire them for a total value of $16 million. This positions Pyxis at the forefront of Antibody-Drug Conjugate (ADC) development.
Comentários